Federal Judge Dismisses AstraZeneca's Lawsuit Against Medicare Drug Price Negotiations

The ruling marks a significant victory for the Biden administration's efforts to lower prescription drug costs through the Inflation Reduction Act.

A federal judge ruled against AstraZeneca, finding the pharmaceutical company lacked standing to challenge Medicare's drug price negotiation program.
The decision upholds the legality of the Inflation Reduction Act's provisions for negotiating drug prices with manufacturers.
AstraZeneca's challenge was based on claims that the negotiation program violated the Fifth Amendment and the Administrative Procedure Act.
This marks the third court victory for the Biden administration in defending the drug price negotiation program against legal challenges.
AstraZeneca expressed disappointment with the ruling and is evaluating its path forward, while the government sees it as a step towards reducing prescription drug costs.